S-1同步放化疗治疗不可手术老年食管癌长期随机III期结果
多中心III期随机试验比较SIB-RT联合口服S-1(CRTCT)与单纯放疗用于≥70岁不可手术局部晚期ESCC,中位随访75个月。CRTCT组OS显著延长(HR 0.74,95%CI 0.57-0.95,P=0.02),5年OS 34.1% vs 23.6%,PFS与RMST亦更优,局部区域失败更少。
要点
- ≥70岁不可手术ESCC,S-1同步放化疗较单纯放疗延长长期OS。
- 5年OS 34.1% vs 23.6%,5年PFS 31.1% vs 20.9%。
- 局部区域失败减少(HR 0.64),远处及混合失败风险相似。
核心结论
- SIB-RT联合口服S-1化疗显著改善老年不可手术ESCC患者的长期生存,可考虑作为标准治疗。
研究设计与样本
- 多中心III期随机临床试验,入组≥70岁不可手术局部晚期II-IV期ESCC患者,随机接受CRTCT或单纯放疗,主要终点为OS。
主要发现
- 中位随访75个月,CRTCT组OS优于RT组(HR 0.74,95%CI 0.57-0.95,P=0.02)。
- 5年OS率34.1% vs 23.6%(P=0.02),5年PFS率31.1% vs 20.9%(P=0.02)。
- RMST为33.0 vs 27.0个月(P=0.02),CRTCT对OS的效应在5年后趋于稳定。
- 局部区域失败低于RT组(HR 0.64,95%CI 0.45-0.92,P=0.02),远处和混合失败风险相似。
关键数值与推荐
- 推荐条款:SIB-RT联合口服S-1化疗可考虑作为≥70岁不可手术ESCC的标准治疗。
临床怎么用
- 对≥70岁不可手术局部晚期ESCC,可评估采用SIB-RT联合口服S-1同步化疗以改善长期生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: This study reports the long-term outcomes of simultaneous integrated boost radiotherapy (SIB-RT) combined with oral S-1 chemotherapy (CRTCT) in inoperable patients aged ≥ 70 years with inoperable esophageal squamous cell carcinoma (ESCC). METHODS: In this multicenter, phase III randomized trial, patients with inoperable, locally advanced stage II-IV ESCC were randomized to receive either CRTCT or RT alone. The primary endpoint was overall survival (OS); secondary endpoints included progression-free survival (PFS), restricted mean survival time (RMST), and patterns of failure. RESULTS: After a median follow-up of 75 months, patients in the CRTCT group had longer OS than those in the RT group (hazard ratio (HR), 0.74; 95 % confidence interval (CI), 0.57-0.95; P = 0.02), with better 5-year OS rates (34.1 % vs. 23.6 %,P = 0.02), PFS (31.1 % vs. 20.9 %,P = 0.02), and RMST (33.0 vs. 27.0 months,P = 0.02). CRTCT's effect on OS stabilized over 5 years. Locoregional failure was lower in the CRTCT group (HR, 0.64; 95 % CI, 0.45-0.92; P = 0.02), with similar distant and mixed failure risks. CONCLUSIONS: SIB-RT combined with oral S-1 chemotherapy significantly improved long-term survival and therefore might be considered a standard of care for elderly patients with inoperable ESCC. TRIAL REGISTRATION Clinical Trials.gov Identifier: NCT0297969.
引用
- Chen J, Chang X, Liu W, et al. Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial. Radiother Oncol. 2025. PMID: 41412437. doi:10.1016/j.radonc.2025.111334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。